Related content

Reply to the letter by Y. Yilmaz regarding ‘‘the AGEs–RAGE axis and nonalcoholic steatohepatitis’’

By Hyogo Hideyuki  

Journal of Gastroenterology, Vol. 45, Iss. 7, 2010-07 ,pp. : 784-784

Springer Publishing Company

Access to resources Recommend Favorite

Pharmacological treatment of non-alcoholic steatohepatitis: The current evidence

By Diakou Maria   Liberopoulos Evangelos   Mikhailidis Dimitri   Tsianos Epaminondas   Burroughs Andrew   Elisaf Moses  

Scandinavian Journal of Gastroenterology, Vol. 42, Iss. 2, 2007-01 ,pp. : 139-147

Informa Healthcare

Access to resources Recommend Favorite

Clinical features of nonalcoholic steatohepatitis in Japan: evidence from the literature

By Ono Masafumi   Saibara Toshiji  

Journal of Gastroenterology, Vol. 41, Iss. 8, 2006-09 ,pp. : 725-732

Springer Publishing Company

Access to resources Recommend Favorite

Hepatocellular carcinoma with nonalcoholic steatohepatitis

By Mori Sayaka   Yamasaki Takahiro   Sakaida Isao   Takami Taro   Sakaguchi Eiki   Kimura Teruaki   Kurokawa Fumie   Maeyama Shiro   Okita Kiwamu  

Journal of Gastroenterology, Vol. 39, Iss. 4, 2004-04 ,pp. : 391-396

Springer Publishing Company

Access to resources Recommend Favorite

Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH

By Kimura Yuki   Hyogo Hideyuki   Yamagishi Sho-ichi   Takeuchi Masayoshi   Ishitobi Tomokazu   Nabeshima Yoshitaka   Arihiro Koji   Chayama Kazuaki  

Journal of Gastroenterology, Vol. 45, Iss. 7, 2010-07 ,pp. : 750-757

Springer Publishing Company

Access to resources Recommend Favorite